Actualización en el diagnóstico y tratamiento | 08 ENE 18
Hidradenitis supurativa
Es una enfermedad inflamatoria de la piel cuya manifestación inicial característica son lesiones dolorosas o supuradas, recidivantes o crónicas, en las zonas con glándulas apócrinas
9
14
Autor: Lindhardt Saunte DT; Borut G; Jemec E JAMA. 2017; 318(20):2019-2032
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1. Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GBE. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231(2):184-190.

2. Lipsker D, Severac F, Freysz M, et al. The ABC of hidradenitis suppurativa: a validated glossary on how to name lesions. Dermatology. 2016;232(2):137-142.

3. Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546-1549.

4. Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J AmAcad Dermatol. 2015;73(5)(suppl 1):S8-S11.

5. Hotz C, Boniotto M, Guguin A, et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol. 2016;136(9):1768-1780.

6. van der Zee HH, de Ruiter L, van den Broecke DG, DikWA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292-1298.

7. Kelly G, Hughes R,McGarry T, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015;173 (6):1431-1439.

8. Ring HC, Bay L, Kallenbach K, et al. Normal skin microbiota is altered in pre-clinical hidradenitis suppurativa. Acta Derm Venereol. 2017;97(2):208-213.

9. Jemec GBE, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J AmAcad Dermatol. 2015;73(5)(suppl 1):S4-S7.

10. IngramJR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa [published online November 1, 2017]. Br J Dermatol. doi:10.1111/bjd.16101

11. Hurley HJ. In: Roenigk RK, Roenigk HH Jr, eds. Dermatologic Surgery: Principles and Practice. 2nd ed. New York: Marcel Dekker; 1996:623-645.

12. Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161(4):831-839.

13. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846-855.

14. Thorlacius L, Garg A, Ingram JR, et al. Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II [published online October 28, 2017]. Br J Dermatol. doi:10.1111/bjd.16093

15. Sampogna F, Abeni D, Gieler U, et al. Impairment of sexual life in 3485 dermatological outpatients from a multicentre study in 13 European countries. Acta Derm Venereol. 2017;97 (4):478-482.

16. Janse IC, Deckers IE, van der Maten AD, et al. Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicenter cross-sectional study. Br J Dermatol. 2017;176(4):1042-1047.

17. Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A. Increased suicide risk in patients with hidradenitis suppurativa [published online September 20, 2017]. J Invest Dermatol. doi:10.1016/j.jid.2017.09.008

18. Vangipuram R, Vaidya T, Jandarov R, Alikhan A. Factors contributing to depression and chronic pain in patients with hidradenitis suppurativa: results from a single-center retrospective review. Dermatology. 2016;232(6):692-695.

19. Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29(2):371-376.

20. Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa [published online February 20, 2012].

J Eur Acad Dermatol Venereol. 2013;27(4):473-478. 21. Miller IM, McAndrew RJ, Hamzavi I. Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):7-16.

22. Riis PT, Boer J, Prens EP, et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J Am Acad Dermatol. 2016;75 (6):1151-1155.

23. Armyra K, Kouris A, Markantoni V, Katsambas A, Kontochristopoulos G. Hidradenitis suppurativa treated with tetracycline in combination with colchicine: a prospective series of 20 patients. Int J Dermatol. 2017;56(3):346-350.

24. Dessinioti C, Zisimou C, Tzanetakou V, Stratigos A, Antoniou C. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. Clin Exp Dermatol. 2016;41(8):852-857.

25. Bettoli V, Zauli S, Borghi A, et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. 2014;28(1):125-126.

26. Join-Lambert O, Coignard-Biehler H, Jais J-P, et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016;71(2):513-520.

27. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434.

28. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846-855.

29. Sotiriou E, Goussi C, Lallas A, et al. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol. 2012;11(5)(suppl):s15-s20.

30. Blok JL, Li K, Brodmerkel C, Horvatovich P, Jonkman MF, Horvath B. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174(4):839-846.

31. Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52-59.

32. Deckers I, Prens E. An update on medical treatment options for hidradenitis suppurativa. Drugs. 2016;76(2):215-229.

33. Alavi A, Kirsner RS. Local wound care and topical management of hidradenitis suppurativa. J AmAcad Dermatol. 2015;73(5)(suppl 1):S55-S61.

34. Boer J, Jemec GB. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol. 2010;35(1):36-40.

35. Bettoli V, Join-Lambert O, Nassif A. Antibiotic treatment of hidradenitis suppurativa. Dermatol Clin.2016;34(1):81-89.

36. Perret LJ, Tait CP. Non-antibiotic properties of tetracyclines and their clinical application in dermatology. Australas J Dermatol. 2014;55(2):111-118.

37. Fischer AH, Haskin A, Okoye GA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J AmAcad Dermatol. 2017;76(2):309-313.e2.

38. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22(5):325-328.

39. Jemec GB,Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J AmAcad Dermatol. 1998;39(6):971-974.

40. Mendonca CO, Griffiths CEM. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154(5):977-978.

41. Kim ES, Garnock-Jones KP, Keam SJ. Adalimumab: a review in hidradenitis suppurativa. Am J Clin Dermatol. 2016;17(5):545-552.

42. Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989-994.

43. Scheinfeld N, Sundaram M, Teixeira H, Gu Y, Okun M. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial. Dermatol Online J. 2016;22(3):13030/qt38x5922j.

44. Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535-545.

45. Giatrakos S, Huse K, Kanni T, et al. Haplotypes of IL-12Rβ1 impact on the clinical phenotype of hidradenitis suppurativa. Cytokine. 2013;62(2):297-301.

46. Blok JL, Boersma M, Terra JB, et al. Surgery under general anaesthesia in severe hidradenitis suppurativa: a study of 363 primary operations in 113 patients. J Eur Acad Dermatol Venereol. 2015;29 (8):1590-1597.

47. Janse IC, Hellinga J, Blok JL, et al. Skin-tissue-sparing excision with electrosurgical peeling: a case series in hidradenitis suppurativa. Acta Derm Venereol. 2016;96(3):390-391.

48. Posch C, Monshi B, Quint T, Vujic I, Lilgenau N, Rappersberger K. The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): retrospective analysis of 74 patients. J AmAcad Dermatol. 2017;77(1):123-129.e5.

49. Romanowski KS, Fagin A,Werling B, et al. Surgical management of hidradenitis suppurativa: a 14-year retrospective review of 98 consecutive patients. J Burn Care Res. 2017;1.

50. Wollina U, Langner D, Heinig B, Nowak A. Comorbidities, treatment, and outcome in severe anogenital inverse acne (hidradenitis suppurativa): a 15-year single center report. Int J Dermatol. 2017; 56(1):109-115.

51. Kohorst JJ, Baum CL, Otley CC, et al. Surgical management of hidradenitis suppurativa: outcomes of 590 consecutive patients. Dermatol Surg. 2016;42(9):1030-1040.

52. van Rappard DC, Mooij JE, Mekkes JR. Mild to moderate hidradenitis suppurativa treated with local excision and primary closure. J Eur Acad Dermatol Venereol. 2012;26(7):898-902.

53. Humphries LS, Kueberuwa E, Beederman M, Gottlieb LJ. Wide excision and healing by secondary intent for the surgical treatment of hidradenitis suppurativa: a single-center experience. J Plast Reconstr Aesthet Surg. 2016;69(4):554-566.

54. Maeda T, Kimura C, Murao N, Takahashi K. Promising long-term outcomes of the reused skin-graft technique for chronic gluteal hidradenitis suppurativa. J Plast Reconstr Aesthet Surg. 2015;68(9):1268-1275.

55. Schmidt M, Dunst-Huemer KM, Lazzeri D, Schoeffl H, Huemer GM. The versatility of the islanded posterior arm flap for regional reconstruction around the axilla. J Plast Reconstr Aesthet Surg. 2015;68(7):953-959.

56. Alharbi Z, Kauczok J, Pallua N. A review of wide surgical excision of hidradenitis suppurativa. BMC Dermatol. 2012;12:9.

57. Wormald JCR, Balzano A, Clibbon JJ, Figus A. Surgical treatment of severe hidradenitis suppurativa of the axilla: thoracodorsal artery perforator (TDAP) flap versus split skin graft. J Plast Reconstr Aesthet Surg. 2014;67(8):1118-1124.

58. Yamashita Y, Hashimoto I, Matsuo S, Abe Y, Ishida S, Nakanishi H. Two-stage surgery for hidradenitis suppurativa: staged artificial dermis and skin grafting. Dermatol Surg. 2014;40(2):110-115.

59. Alharbi M, Perignon D, Assaf N, Qassemyar Q, Elsamad Y, Sinna R. Application of the inner arm perforator flap in the management of axillary

hidradenitis suppurativa. Ann Chir Plast Esthet. 2014;59(1):29-34.

60. Mutaf M, Gunal E, Berberoğlu O, Gokce A. Surgical treatment of extensive sacrococcygeal hidradenitis suppurativa with triangular closure technique. Ann Plast Surg. 2014;73(5):583-587.

61. Nesmith RB, Merkel KL, Mast BA. Radical surgical resection combined with lymphadenectomy-directed antimicrobial therapy yielding cure of severe axillary hidradenitis. Ann Plast Surg. 2013;70(5):538-541.

62. Wollina U, Tilp M, Meseg A, Schonlebe J, Heinig B, Nowak A. Management of severe anogenital acne inversa (hidradenitis suppurativa). Dermatol Surg. 2012;38(1):110-117.

63. DeFazio MV, Economides JM, King KS, et al. Outcomes after combined radical resection and targeted biologic therapy for the management of recalcitrant hidradenitis suppurativa. Ann Plast Surg. 2016;77(2):217-222.

64. Van Rappard DC, Mekkes JR. Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions. Br J Dermatol. 2012;167(1):206-208.

65. IngramJR,Woo P-N, Chua SL, et al. Interventions for hidradenitis suppurativa. Cochrane Database Syst Rev. 2015;(10):CD010081.

66. Mehdizadeh A, Hazen PG, Bechara FG, et al. Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. J AmAcad Dermatol. 2015;73(5)(suppl 1):S70-S77.

67. Janse I, Bieniek A, Horvath B, Matusiak Ł. Surgical procedures in hidradenitis suppurativa. Dermatol Clin. 2016;34(1):97-109.

68. Jemec GB, Guerin A, Kaminsky M, Okun M, Sundaram M. What happens after a single surgical intervention for hidradenitis suppurativa? a retrospective claims-based analysis. J Med Econ. 2016;19(7):710-717.

69. Ozer İ, Karacin C, Adışen E, Guz G, Ali Gurer M. Two diseases one remedy? systemic amyloidosis secondary to hidradenitis suppurativa: treatment with infliximab. Dermatol Ther. 2017;30(2).

70. Utrera-Busquets M, Romero-Mate A, Castano A, Alegre L, Garcia-Donoso C, Borbujo J. Severe hidradenitis suppurativa complicated by renal AA amyloidosis. Clin Exp Dermatol. 2016;41(3):287-289.

71. Makris GM, Poulakaki N, Papanota AM, Kotsifa E, Sergentanis TN, Psaltopoulou T. Vulvar, perianal and perineal cancer after hidradenitis suppurativa: a systematic review and pooled analysis. Dermatol Surg. 2017;43(1):107-115.

72. Kromann CB, Ibler KS, Kristiansen VB, Jemec GBE. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94(5):553-557.

73. Kromann CB, Deckers IE, Esmann S, Boer J, Prens EP, Jemec GBE. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171(4):819-824.

74. Mikkelsen PR, Dufour DN, Zarchi K, Jemec GBE. Recurrence rate and patient satisfaction of CO2 laser evaporation of lesions in patients with hidradenitis suppurativa: a retrospective study. Dermatol Surg. 2015;41(2):255-260.

75. Esmann S, Dufour DN, Jemec GBE. Questionnaire-based diagnosis of hidradenitis suppurativa: specificity, sensitivity and positive predictive value of specific diagnostic questions. Br J Dermatol. 2010;163(1):102-106.

76. Lookingbill DP. Yield from a complete skin examination: findings in 1157 new dermatology patients. J AmAcad Dermatol. 1988;18(1 pt 1):31-37.Clinical Review & Education Review Advances in Diagnosis and Treatment of Hidradenitis Suppurativa 2032

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí